❤️ contento tras concluir el II CARE ME! Ha sido un lujo contar con todos vosotros en @vallhebron! GRACIAS a moderadores, ponentes y a todos los asistentes que lo habéis hecho posible! Os esperamos el año que viene en @hospitalclinic!!
(10/x) Part 4: Together we conquer
Very quickly our hero realizes he cannot beat the boss alone. He teams up with other specialties in the palace.
Although initially these other teams are not supportive, with time and nurturing of these relationships they come on board and realize that thoughtful integration (just to clarify the artifact is #pocus in case this extended metaphor has been lost at this point...) results in better care.
The new team fights the final boss together.
Ex vivo C5b-9 Deposition Test to Monitor Complement Activity in Clinical and Subclinical Atypical Hemolytic Uremic Syndrome and in Transplantation-Associated Thrombotic Microangiopathy - Kidney International Reports https://t.co/UpNQuVUMAh Congrats @ConxitaJacobs 👏👏👏
Recordando Cursos de Electrolitos: ¿Para que sirve el suero salino hipertónico? No busques demasiado. Sólo para tres cosas: Hiponatremia sintomática, insuficiencia cardiaca grave y edema cerebral. ¿Para algo más? 🤔
@SENefrologia@SOMANEorg#Nefro_8_01
The moment you have been waiting for arrived! EVA Meeting takes place on June 14th & 15th: the best scientists will highlight everything that is new and interesting in Vascular Access! #EVAmeeting#VAscularAccess#EndoVascularAccess
https://t.co/slSwysQxVY
It's here! The KDIGO 2024 CKD Guideline Executive Summary was released today in the April Issue of Kidney International (KI).
Read the Executive Summary in KI: https://t.co/iDJ6ELa4C5
Download the PDF: https://t.co/zQhDLRNFGi
The KDIGO 2024 CKD Guideline, based on the best current evidence, indicates exciting new approaches to management strategies and treatment options for people living with #CKD. The goal is to improve symptom management, disease modification, and person-centered approaches while also recognizing the heterogeneity of CKD. The fact that new therapies exist and others are being evaluated heralds an exciting time for people living with #kidney diseases.
🔍 Uncover the latest addition to ISN's toolkit tackling Complement-Mediated Kidney Diseases (CMKDs)! 🤓 This comprehensive toolkit offers insights into the intricate world of the complement system and its correlation with kidney diseases.
🌐 Despite being less familiar and deemed rare, CMKDs are a vital and complex facet of kidney health that warrants greater acknowledgment for optimal care.
Dive into the ISN's CMKDs toolkit: https://t.co/ZW2q3q01ei
A big shoutout to @NickRhysMT for his invaluable contribution! 🙌
KDIGO is pleased to announce the publication of the 2024 Clinical Practice Guideline for the Management of Lupus Nephritis, published today in the January 2024 issue of Supplement to Kidney International, with an Executive Summary published in the main pages of the journal.
Read the news release: https://t.co/hd8O3bCSEY
Read the guideline in Kidney International: https://t.co/reqtpXWFk8
Download the guideline: https://t.co/Kqcmmu929y
Developed under the stewardship of Co-Chairs Brad Rovin, MD (US) and Jürgen Floege, MD (DE), this guideline is an update of the Lupus Nephritis (LN) chapter of the KDIGO 2021 Glomerular Diseases Guideline.
"We are thrilled to publish the Lupus Nephritis Guideline, which follows only two years after the publication of the KDIGO Glomerular Diseases Guideline and reflects the latest advancements in the field,” said Dr. Rovin. "This guideline offers critical insights into navigating the complexities of LN treatment, especially with the introduction of novel therapies, and highlights the need for individualized therapy selection based on patient-specific factors and clinical scenarios. With ongoing trials evaluating additional novel therapeutics and promising new data on the horizon, the guideline sets the stage for future advancements in the management and treatment of LN.”
"This guideline includes several key updates to inform clinical decision-making, leveraging the latest evidence to integrate new treatments into the arsenal of established clinical standards,” said Dr. Floege. “A section on chronic kidney disease progression in LN underscores the importance of addressing broader kidney health concerns beyond acute treatment. We hope the rigorous research, clinical insights, and collective expertise represented in this guideline will help improve outcomes for those affected by this challenging condition.”
KDIGO thanks the Guideline Work Group for their dedication and expertise and the Evidence Review Team from Brown University School of Public Health for their comprehensive work on this guideline.
#lupus #lupusnephritis
📣 𝗜𝗦𝗡 𝗠𝗘𝗠𝗕𝗘𝗥 𝗘𝗫𝗖𝗟𝗨𝗦𝗜𝗩𝗘: Discover the ISN Academy's pioneering Social Media Education curriculum designed to equip you with the tools and skills needed to thrive in the digital landscape of learning. From December 2023 till April 2024: 9 modules will be released ��️ https://t.co/yTuHowWdwT
The expert faculty, led by esteemed individuals in the field, will guide you through each session, providing practical insights and hands-on training. One module will be delivered in partnership with @NSMCInternship
Biopsia en trasplantes con viremia BK⁉️Interesante 👏Estudio multicèntrico 🇪🇺con participación del
@kidney_mar👏SENefrologia @SETrasplante https://t.co/9AQpqgb0DF
What are the recent developments in cardiology? Catch up on all the top stories and new guidelines from this year’s ESC Congress with our expert coverage.
Calentando motores para la que será una de las mejores ediciones de nuestro congreso #GEMAV23
💥Curso de actualización en el acceso vascular (4 de octubre)
💥Workshops médico y de enfermería (5 de octubre)
💥V Congreso (6 y 7 de octubre)
📲Inscríbete en https://t.co/h2GKhr92lg